- Home
- VNOM vs IONS Comparison
VNOM vs IONS Comparison
Compare VNOM & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNOM
- IONS
- Stock Information
- Founded
- VNOM 2013
- IONS 1989
- Country
- VNOM United States
- IONS United States
- Employees
- VNOM N/A
- IONS N/A
- Industry
- VNOM Oil & Gas Production
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- VNOM Energy
- IONS Health Care
- Exchange
- VNOM Nasdaq
- IONS Nasdaq
- Market Cap
- VNOM 6.3B
- IONS 6.8B
- IPO Year
- VNOM 2014
- IONS 1991
- Fundamental
- Price
- VNOM $38.07
- IONS $71.42
- Analyst Decision
- VNOM Strong Buy
- IONS Strong Buy
- Analyst Count
- VNOM 13
- IONS 20
- Target Price
- VNOM $54.58
- IONS $75.55
- AVG Volume (30 Days)
- VNOM 1.6M
- IONS 2.0M
- Earning Date
- VNOM 11-03-2025
- IONS 10-29-2025
- Dividend Yield
- VNOM 6.45%
- IONS N/A
- EPS Growth
- VNOM 16.12
- IONS N/A
- EPS
- VNOM 3.30
- IONS N/A
- Revenue
- VNOM $932,200,000.00
- IONS $944,050,000.00
- Revenue This Year
- VNOM $74.62
- IONS $24.01
- Revenue Next Year
- VNOM $39.87
- IONS $4.06
- P/E Ratio
- VNOM $11.50
- IONS N/A
- Revenue Growth
- VNOM 5.03
- IONS 16.05
- 52 Week Low
- VNOM $34.71
- IONS $23.95
- 52 Week High
- VNOM $56.76
- IONS $74.42
- Technical
- Relative Strength Index (RSI)
- VNOM 52.06
- IONS 71.05
- Support Level
- VNOM $35.65
- IONS $70.47
- Resistance Level
- VNOM $37.25
- IONS $74.42
- Average True Range (ATR)
- VNOM 1.04
- IONS 1.78
- MACD
- VNOM 0.05
- IONS -0.48
- Stochastic Oscillator
- VNOM 59.34
- IONS 58.11
About VNOM Viper Energy Inc.
Viper Energy Inc is focused on owning and acquiring mineral and royalty interests in oil and natural gas properties in the Permian Basin. The Permian Basin is known to have a number of zones of oil and natural gas-bearing rock throughout.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.